Enhanced conversion of triglyceride-rich lipoproteins and increased low-density lipoprotein removal in LPLS447X carriers

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 25, Issue 11, 2005, Pages 2410-2415

  Nierman, Melchior C ^a   Prinsen, Berthil H C M T ^b   Rip, Jaap ^a   Veldman, Robert Jan ^a   Kuivenhoven, Jan Albert ^a   Kastelein, John J P ^a   De Sain Van Der Velden, Monique G M ^b   Stroes, Erik S G ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

apoB100; Apolipoproteins; Lipoprotein lipase; LPLS447X; Metabolism

Indexed keywords

APOLIPOPROTEIN B100; CARBON 13; INTERMEDIATE DENSITY LIPOPROTEIN; LIPOPROTEIN; LIPOPROTEIN LIPASE; LOW DENSITY LIPOPROTEIN; TRIGLYCERIDE RICH LIPOPROTEIN; UNCLASSIFIED DRUG; VALINE; VERY LOW DENSITY LIPOPROTEIN;

ADULT; ARTICLE; CHOLESTEROL TRANSPORT; ENZYME ACTIVITY; HEART PROTECTION; HETEROZYGOTE; HOMOZYGOSITY; HUMAN; HUMAN EXPERIMENT; HYDROLYSIS; ISOTOPE LABELING; LIPID METABOLISM; MALE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN TRANSPORT;

ADULT; ANTICOAGULANTS; APOLIPOPROTEIN B-100; APOLIPOPROTEINS B; ATHEROSCLEROSIS; CARBON ISOTOPES; DIETARY FATS; HEPARIN; HETEROZYGOTE; HOMOZYGOTE; HUMANS; LIPOPROTEIN LIPASE; LIPOPROTEINS, LDL; LIPOPROTEINS, VLDL; MALE; MIDDLE AGED; POINT MUTATION; TRIGLYCERIDES; VALINE;

EID: 27644544431     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000188506.79946.ce     Document Type: Article

References (30)

1. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk. 1996;3:213-219.
2. Krauss RM. Atherogenicity of triglyceride-rich lipoproteins. Am J Cardiol. 1998;81:13B-17B.
3. Milosavljevic D, Kontush A, Griglio S. Le Naour G, Thillet J, Chapman MJ. VLDL-induced triglyceride accumulation in human macrophages is mediated by modulation of LPL lipolytic activity in the absence of change in LPL mass. Biochim Biophys Acta. 2003;1631:51-60.
4. Libby P, Ridker PM. Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105:1135.
5. Merkel M, Heeren J. Dudeck W, Rinninger F, Radner H, Breslow JL, Goldberg IJ, Zechner R, Greten H. Inactive lipoprotein lipase (LPL) alone increases selective cholesterol ester uptake in vivo, whereas in the presence of active LPL it also increases triglyceride hydrolysis and whole particle lipoprotein uptake. J Biol Chem. 2002;277:7405-7411.
6. Heeren J. Niemeier A. Merkel M, Beisiegel U. Endothelial-derived lipoprotein lipase is bound to postprandial triglyceride-rich lipoproteins and mediates their hepatic clearance in vivo. J Mol Med. 2002;80:576-584.
7. Casaroli-Marano RP, Garcia R. Vilella E, Olivecrona G, Reina M, Vilaro S. Binding and intracellular trafficking of lipoprotein lipase and triacylglycerol-rich lipoproteins by liver cells. J Lipid Res. 1998;39:789-806.
8. Wittrup HH, Tybjaerg-Hansen A, Nordestgaard BG. Lipoprotein lipase mutations, plasma lipids and lipoproteins, and risk of ischemic heart disease. A meta-analysis. Circulation. 1999;99:2901-2907.
9. Mero N, Suurinkeroinen L. Syvanne M, Knudsen P, Yki-Jarvinen H, Taskinen MR. Delayed clearance of postprandial large TG-rich particles in normolipidemic carriers of LPL Asn291Ser gene variant. J Lipid Res. 1999;40:1663-1670.
10. Kozaki K, Gotoda T, Kawamura M, Shimano H, Yazaki Y, Ouchi Y, Orimo H, Yamada N. Mutational analysis of human lipoprotein lipase by carboxy-terminal truncation. J Lipid Res. 1993;34:1765-1772.
11. Zhang H, Henderson H, Gagne SE, Clee SM, Miao L, Liu G, Hayden MR. Common sequence variants of lipoprotein lipase: standardized studies of in vitro expression and catalytic function. Biochim Biophys Acta. 1996;1302:159-166.
12. Kuivenhoven JA, Groenemeyer BE, Boer JMA, Reymer PWA, Berghuis R, Bruin T, Jansen H, Seidell JC. Kastelein JJP. Ser447stop mutation in lipoprotein lipase is associated with elevated HDL cholesterol levels in normolipidemic males. Arterioscler Thromb Vasc Biol. 1997;17:595-599.
13. de Sain-van der Velden M. Rabelink TJ, Gadellaa MM, Elzinga H, Reijngoud DJ, Kuipers F, Stellaard F. In vivo determination of very-low-density lipoprotein-apolipoprotein B100 secretion rates in humans with a low dose of-[1-13C] valine and isotope ratio mass spectrometry. Anal Biochem. 1998;265:308-312.
14. Prinsen BHCM, Romijn JA, Bisschop PH, de Barse MMJ, Barren PH, Ackermans M, Berger R, Rabelink TJ, de Sain-van der Velden M. Endogenous cholesterol synthesis is associated with VLDL-2 apoB-100 production in healthy humans. J Lipid Res. 2003;44:1341-1348.
15. Kastelein JJ, Jukema JW, Zwinderman AH, Clee S, van Boven AJ, Jansen H, Rabelink TJ, Peters RJ, Lie KI, Liu G, Bruschke AV, Hayden MR. Lipoprotein lipase activity is associated with severity of angina pectoris. REGRESS Study Group. Circulation. 2000;102:1629-1633.
16. Prinsen BHCM, Rabelink TJ, Romijn JA, Bisschop PH, de Barse MMJ, de Boer J, van Haeften TW, Barrett PH, Berger R, de Sain-van der Velden M. A broad-based metabolic approach to study VLDL apoB100 metabolism in patients with ESRD and patients treated with peritoneal dialysis. Kidney Int. 2004;65:1064-1075.
17. Pruneta V, Autran D, Ponsin G, Marcais C, Duvillard L, Verges B, Berthezene F, Moulin P. Ex vivo measurement of lipoprotein lipase-dependent very low density lipoprotein (VLDL)-triglyceride hydrolysis in human VLDL: an alternative to the postheparin assay of lipoprotein lipase activity? J Clin Endocrinol Metab. 2001;86:797-803.
18. Garenc C, Perusse L, Gagnon J, Chagnon YC, Bergeron J, Despres JP, Province MA, Leon AS, Skinner JS, Wilmore JH, Rao DC, Bouchard C. Linkage and association studies of the lipoprotein lipase gene with post-heparin plasma lipase activities, body fat, and plasma lipid and lipoprotein concentrations: the HERITAGE Family Study. Metabolism. 2000;49:432-439.
19. Mulder M, Lombardi P, Jansen H, van Berkel TJ, Frants RR, Havekes LM. Low density lipoprotein receptor internalizes low density and very low density lipoproteins that are bound to heparan sulfate proteoglycans via lipoprotein lipase. J Biol Chem. 1993;268:9369-9375.
20. Rumsey SC, Obunike JC, Arad Y, Deckelbaum RJ, Goldberg IJ. Lipoprotein lipase-mediated uptake and degradation of low density lipoproteins by fibroblasts and macrophages. J Clin Invest. 1992;90:1504-1512.
21. Vilella E, Joven J, Fernandez M, Vilaro S, Brunzell JD, Olivecrona T, Bengtsson-Olivecrona G. Lipoprotein lipase in human plasma is mainly inactive and associated with cholesterol-rich lipoproteins. J Lipid Res. 1993;34:1555-1564.
22. Tilly-Kiesi M, Schaefer EJ, Knudsen P, Welty FK, Dolnikowski GG, Taskinen MR, Lichtenstein AH. Lipoprotein metabolism in subjects with hepatic lipase deficiency. Metabolism. 2004;53:520-525.
23. Welty FK, Lichtenstein AH, Barrett PH, Dolnikowski GG, Ordovas JM, Schaefer EJ. Production of apolipoprotein B-67 in apolipoprotein B-67/B-100 heterozygotes: technical problems associated with leucine contamination in stable isotope studies. J Lipid Res. 1997;38:1535-1543.
24. Ouguerram K, Magot T, Zair Y, Marchini JS, Charbonnel B, Laouenan H, Krempf M. Effect of atorvastatin on apolipoprotein B100 containing lipoprotein metabolism in type-2 diabetes. J Pharmacol Exp Ther. 2003;306:332-337.
25. Batista MC, Welty FK, Diffenderfer MR, Sarnak MJ, Schaefer EJ, Lamon-Fava S, Asztalos BF, Dolnikowski GG, Brousseau ME, Marsh JB. Apolipoprotein A-I, B-100, and B-48 metabolism in subjects with chronic kidney disease, obesity, and the metabolic syndrome. Metabolism. 2004;53:1255-1261.
26. Marsh JB, Welty FK, Lichtenstein AH, Lamon-Fava S, Schaefer EJ. Apolipoprotein B metabolism in humans: studies with stable isotope-labeled amino acid precursors. Atherosclerosis. 2002;162:227-244.
27. Welty FK, Lichtenstein AH, Barrett PH, Dolnikowski GG, Ordovas JM, Schaefer EJ. Decreased production and increased catabolism of apolipoprotein B-100 in apolipoprotein B-67/B-100 heterozygotes. Arterioscler Thromb Vasc Biol. 1997;17:881-888.
28. Groenemeijer BE, Hallman MD, Reymer PW, Gagne E, Kuivenhoven JA, Bruin T, Jansen H, Lie KI, Bruschke AV, Boerwinkle E, Hayden MR, Kastelein JJ. Genetic variant showing a positive interaction with beta-blocking agents with a beneficial influence on lipoprotein lipase activity, HDL cholesterol, and triglyceride levels in coronary artery disease patients. The Ser447-stop substitution in the lipoprotein lipase gene. REGRESS Study Group. Circulation. 1997;95:2628-2635.
29. Lee J, Tan CS, Chia KS, Tan CE, Chew SK, Ordovas JM, Tai ES. The lipoprotein lipase S447X polymorphism and plasma lipids: interactions with APOE polymorphisms, smoking, and alcohol consumption. J Lipid Res. 2004;45:1132-1139.
30. Wittrup HH, Nordestgaard BG, Steffensen R, Jensen G, Tybjaerg-Hansen A. Effect of gender on phenotypic expression of the S447X mutation in LPL: the Copenhagen City Heart Study. Atherosclerosis. 2002;165:119-126.